Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL782733 | 0.78 | BRPF1 (0.42) | CYP11B2KCNJ1GPR55DDB1CRBN | |
| SCHEMBL801469 | 0.73 | GPR55 (0.54) | CYP11B2KCNJ1GPR55DDB1CRBN | |
| SCHEMBL783680 | 0.72 | CYP11B2 (0.47) | CYP11B2KCNJ1GPR55DDB1CRBN | |
| SCHEMBL782823 | 0.72 | CYP11B2 (0.58) | CYP11B2KCNJ1GPR55DDB1CRBN | |
| SCHEMBL782507 | 0.71 | CYP11B2 (0.48) | CYP11B2KCNJ1GPR55DDB1CRBN | |
| SCHEMBL783358 | 0.71 | CYP11B2 (0.49) | CYP11B2KCNJ1GPR55L3MBTL1 | |
| SCHEMBL782548 | 0.70 | CYP11B2 (0.48) | CYP11B2KCNJ1GPR55KMT2ALMNA | |
| SCHEMBL782795 | 0.70 | CYP11B2 (0.47) | CYP11B2KCNJ1GPR55 | |
| SCHEMBL783487 | 0.70 | KCNJ1 (0.51) | CYP11B2KCNJ1GPR55 | |
| SCHEMBL805385 | 0.69 | GPR55 (0.46) | CYP11B2KCNJ1GPR55KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430018-B1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B2, CYP11B1, CYP21A2 | CYP11B2 1/4885KCNJ1 630/4885GPR55 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.